LDD175

LDD175 is a small molecule benzofuroindole derivative that functions as a potent and selective opener of large-conductance Ca2-activated potassium (BKCa) channels. Its primary mechanism of action is to induce smooth muscle relaxation via endothelium-independent activation of BKCa channels, thereby improving erectile function and relaxing bladder and prostate smooth muscle. Preclinical studies in animal models have shown dose-dependent therapeutic efficacy of LDD175 in erectile dysfunction (ED) and lower urinary tract symptoms (LUTS), with additive or synergistic effects when combined with phosphodiesterase type 5 inhibitors (such as sildenafil) or α1-adrenergic antagonists (such as tamsulosin) and 5α-reductase inhibitors (such as finasteride). The compound has demonstrated favorable safety profiles in animal studies, with no significant adverse effects reported and promising results for further development in urological indications, including benign prostatic hyperplasia (BPH) and chronic pelvic ischemia-associated ED and LUTS[1][2][3][5][7][8][9].

Other names

4-chloro-7-trifluoromethyl-10H-benzo[4,5]furo[3,2-b]indole-1-carboxylic acid